QCG
MRVI icon

Quadrant Capital Group’s Maravai LifeSciences MRVI Stock Holding History

Quadrant Capital Group’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.3K Hold
11,075
– – ﹤0.01% 1855
2025
Q4 		$36K Hold
11,075
– – ﹤0.01% 1794
2025
Q3 		$31.8K Buy
+11,075
New +$28.3K ﹤0.01% 1810
2025
Q2 		– Sell
-5,940
Closed -$13.1K – 2114
2025
Q1 		$13.1K Buy
5,940
+4,263
+254% +$16.8K ﹤0.01% 2152
2024
Q4 		$9.14K Sell
1,677
-1,940
-54% -$12.5K ﹤0.01% 2151
2024
Q3 		$30.1K Sell
3,617
-1,114
-24% -$9.63K ﹤0.01% 1723
2024
Q2 		$33.9K Sell
4,731
-204
-4% -$1.76K ﹤0.01% 1607
2024
Q1 		$42.8K Buy
4,935
+1,666
+51% +$11.3K ﹤0.01% 1483
2023
Q4 		$21.4K Buy
3,269
+3
+0.1% +$19 ﹤0.01% 1789
2023
Q3 		$32.7K Buy
3,266
+2,511
+333% +$27.6K ﹤0.01% 1472
2023
Q2 		$9.38K Sell
755
-1,578
-68% -$21.3K ﹤0.01% 2016
2023
Q1 		$32.7K Buy
2,333
+1,688
+262% +$24.2K ﹤0.01% 1456
2022
Q4 		$9.23K Buy
645
+429
+199% +$6.75K ﹤0.01% 1987
2022
Q3 		$6K Buy
+216
New +$5.42K ﹤0.01% 2079
2022
Q1 		– Sell
-4
Closed – – 2621
2021
Q4 		$0 Hold
4
– – ﹤0.01% 2631
2021
Q3 		$0 Buy
+4
New +$195 ﹤0.01% 2594

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Quadrant Capital Group's MRVI Position: Q1 2026 in Review

Quadrant Capital Group held its Maravai LifeSciences (MRVI) position steady in Q1 2026 at 11,075 shares worth $31.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1855.

Quadrant Capital Group first reported a position in MRVI in Q3 2021 and has held it in 16 quarters since. The position peaked at $42.8K in Q1 2024. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Quadrant Capital Group held 11,075 shares of Maravai LifeSciences worth $31.3K as of Q1 2026.
  • Quadrant Capital Group left its Maravai LifeSciences share count unchanged in Q1 2026.
  • Maravai LifeSciences made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #1855 holding.
  • Quadrant Capital Group first reported a position in Maravai LifeSciences in Q3 2021 and has held it in 16 quarters since.
  • Quadrant Capital Group's Maravai LifeSciences position peaked at $42.8K in Q1 2024.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.